Search Results for “cancer” – Page 20 – media

Pfizer Teams With American Cancer Society to Reduce Cancer Care Disparities

Pfizer announced a partnership with the American Cancer Society aimed at reducing disparities in cancer treatment. As part of the initiative, Pfizer is providing $15 million in funding. This money will go towards improving the health outcomes of cancer patients from underrepresented communities in the United States. This will include working to improve access to cancer screenings, clinical trial opportunities, and patient care. In a press release, Pfizer’s chief oncology officer and executive vice president Chris Boshoff said, “Cancer doesn’t discriminate–and neither should cancer care. Everyone should have the same opportunity to access the latest advances in care, regardless of their background or where they live. We’re proud to partner with the American Cancer Society on a broad, community-focused initiative to reach people living with cancer where they are, with urgency, and connect them to resources to receive the care they deserve.” The partnership will work under the banner of ...
- Source: drugdu
- 74
- February 8, 2024
Non-Endoscopic Capsule Sponge Device Helps Detect Esophageal Cancer

Barrett’s esophagus is a condition often resulting from reflux, characterized by stomach acid damaging the esophagus lining and causing cell changes. While these cells aren’t initially cancerous, there’s a risk they might transform into esophageal cancer, a type where cells in the esophagus proliferate uncontrollably, potentially spreading to other body parts. Esophageal cancer is among the deadliest cancers in adults, and early detection significantly improves survival rates compared to a diagnosis at an advanced stage. Since the symptoms of esophageal cancer can mimic heartburn and reflux, conducting early tests for cancer detection is crucial. Now, a non-endoscopic capsule sponge device has been designed to collect pan-esophageal samples which are then sent for laboratory testing to detect esophageal pre-cancer and other conditions. Cyted’s (Cambridge, UK) EndoSign cell collection device is designed to detect and monitor conditions such as chronic reflux and Barrett’s esophagus, ultimately aiming to prevent esophageal adenocarcinoma. The EndoSign ...
- Source: drugdu
- 83
- February 8, 2024
Hengrui ADC Innovative Drug SHR-A1811 HER2 Positive Gastric Cancer Indication Proposed to be Included in Breakthrough Therapy Variety

This study was led by Professor Jin Li of Dongfang Hospital, Tongji University, with the participation of a total of 17 centers across China. Previously, four other indications of SHR-A1811 have been included in the list of breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration, and the indications are: recurrent or metastatic breast cancer with low expression of HER2, HER2-positive recurrent or metastatic breast cancer, HER2-mutated advanced non-small-cell lung cancer that has failed previous platinum-containing chemotherapy, and advanced non-small-cell lung cancer that has failed previous treatments of oxaliplatin, fluorouracil, and irinotecan, and has failed previous treatments of oxaliplatin, fluorouracil, and irinotecan. irinotecan treatment failure, and HER2-positive colorectal cancer. In 2020, gastric cancer ranks 5th in global cancer incidence and 4th in mortality. HER2-positive gastric cancer is a unique disease subtype that requires different treatment strategies from HER2-negative gastric cancer. The global HER2-positive rate of gastric ...
- Source: drugdu
- 109
- February 6, 2024
Neural Network Recognizes Breast Cancer on Histological Samples With 100% Accuracy

The likelihood of a favorable outcome for a breast cancer patient is greatly influenced by the stage at which the cancer is diagnosed. Histological examination is the benchmark for diagnosis, but its reliability can be affected by subjective interpretations and the quality of the tissue sample. Inaccuracies in these examinations can lead to incorrect diagnoses. Now, a team of mathematicians has developed a machine learning model that significantly enhances the accuracy of identifying cancer in histological images. The highlight of this model is the incorporation of an additional module that boosts the neural network’s “attention” capability, enabling it to achieve near-perfect accuracy. The mathematicians at RUDN University (Moscow, Russia) conducted tests on several convolutional neural networks and supplemented them with two convolutional attention modules. These modules are crucial for detecting objects within images. The model underwent training and testing using the BreakHis dataset, which comprises nearly 10,000 histological images at ...
- Source: drugdu
- 81
- February 5, 2024
New Method Enables Detection of Lung Cancer through Blood Tests

Lung cancer continues to be a very deadly disease with only 19% of diagnosed patients remaining alive after five years. This makes it important to accurately detect the different forms of lung cancer, each with its own treatment and approach, at an early stage so that patients can be better treated. Currently, there is a gold standard for determining whether someone has lung cancer. If suspected, the first step is a scan, such as CT or PET CT. That gives insight into where the symptoms may be coming from and the location of possible cancer cells or a tumor. The second step is a biopsy in which a ‘morsel’ of tissue is removed and examined under the microscope. However, evidence of tumor cells cannot always be obtained. Additionally, sometimes people are too old or too sick and the biopsy itself is too risky for their health. Also, sometimes people refuse ...
- Source: drugdu
- 84
- February 5, 2024
Innovative ‘Fragmentomics’ Approach to Enable Earlier Detection of Cancer Using Smaller Blood Draws

When cells die, they disintegrate, releasing part of their DNA material into the bloodstream. This cell-free DNA (cfDNA) contains cancer signals. The cfDNA from healthy cells breaks down into standard-sized fragments, whereas cancerous cfDNA fragments disintegrate at different locations, often in the genome’s repetitive regions. Instead of searching for specific DNA mutations, which is like finding a single misarranged letter in billions of letters, researchers have developed a novel machine-learning method. This method detects variations in fragmentation patterns between cancerous and normal cfDNA in these repetitive regions of cancer. This groundbreaking technique could potentially allow for earlier cancer detection in patients through smaller blood samples, as it requires approximately eight times less blood than what is needed for whole genome sequencing. The algorithm called Alu Profile Learning Using Sequencing (A-Plus) was developed by researchers at City of Hope (Duarte, CA, USA) and Translational Genomics Research Institute (TGen, Phoenix, AZ, USA). ...
- Source: drugdu
- 147
- February 2, 2024
Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness

Approximately only half of cancer patients see a positive response to treatments, with the remaining experiencing inadequate outcomes. The high costs and potential adverse reactions of treatments make it crucial for clinicians to quickly determine their effectiveness, or if an alternative therapy is more suitable. Presently, it can take weeks or months to fully gauge the success of cancer treatment, typically using CT scans to measure significant size changes in tumors. While tumor biopsies offer more precise data, their infrequency limits the ability to provide ongoing updates. As a solution, many clinicians are now resorting to liquid biopsies, which involve testing for cancer indicators in a patient’s blood, like tumor-shed cancer cells. However, these tests require sufficiently high cell levels for detection. This is particularly challenging in lung cancer, where some FDA-approved methods for detecting blood-borne cancer cells are ineffective, often due to targeting a single, less common protein in ...
- Source: drugdu
- 142
- February 1, 2024
AI-Based Blood Test Detects Ovarian Cancer With 93% Accuracy

Ovarian cancer, often termed the silent killer, typically presents no symptoms in its initial stages, leading to late detection when treatment becomes challenging. The stark contrast in survival rates highlights the urgent need for early diagnosis: while late-stage ovarian cancer patients have a five-year survival rate of around 31% post-treatment, early detection and treatment can raise this rate to over 90%. Despite over three decades of research, developing an accurate early diagnostic test for ovarian cancer has proved challenging. This difficulty stems from the disease’s molecular origins, where multiple pathways can lead to the same cancer type. Scientists at the Georgia Tech Integrated Cancer Research Center (ICRC, Atlanta, GA, USA) have now made a breakthrough by integrating machine learning with blood metabolite information, developing a test that can detect ovarian cancer with 93% accuracy in their study group. This test outperforms existing detection methods, especially in identifying early-stage ovarian disease ...
- Source: drugdu
- 106
- February 1, 2024
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 30, 2024: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). ELUNATE® is a selective oral inhibitor of vascular endothelial growth factor (“VEGF”) receptors -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis. This marks the first medicine to be approved under the new mechanism for registration of new drugs (“1+” mechanism) announced by the Government of the Hong Kong Special Administrative Region (“SAR”) in October last year. The mechanism officially commenced on November 1, 2023. It allows drugs which are beneficial for treatment of life-threatening or severely debilitating diseases to apply for registration for use in Hong Kong, if they have supporting local clinical data and recognition ...
- Source: drugdu
- 106
- February 1, 2024
Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

Shanghai, China – January 28,2024- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the first-time release of interim analysis data for the Phase II clinical trial of oral APL-1202 in combination with the PD-1 inhibitor tislelizumab for neoadjuvant treatment of muscle-invasive bladder cancer (MIBC). Release of the interim analysis data was made in the form of a rapid oral presentation abstract (Abstract No:632）at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). Patient enrollment of the trial was recently completed. Primary objective of the Phase II clinical trial is to evaluate the safety and efficacy of APL-1202 in combination with tislelizumab compared to tislelizumab monotherapy as neoadjuvant therapy for MIBC patients. The trial population includes patients with newly diagnosed MIBC for whom radical cystectomy (RC) is planned, ...
- Source: drugdu
- 93
- January 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.